Elderly hip fracture
Conditions
Interventions
Experimental group:patients underwent continuous nerve block analgesia in iliac fascia region under ultrasound guidance.
Control group:The patient took celecoxib capsules (trade name: Celebrex) 0.2g each time, twice a day
Sponsors
Department of Anesthesiology, Gezhouba Central Hospital, Sinopath
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age>=65 years old; 2. Patients with PFNA for hip fractures; 3. Consciousness is clear and there is no communication barrier; 4. ASA grade I.~III.; 5. Preoperative hypertension and diabetes and other co-existing diseases are well controlled; 6. Patients and their families are aware of the research content and voluntarily participate in the research.
Exclusion criteria
Exclusion criteria: 1. Those with central nervous system or psychological diseases; 2. Those who have mental illness before surgery and cannot communicate; 3. Those who cannot cooperate with treatment for various reasons; 4. Patients with severe liver and kidney insufficiency, coagulation dysfunction or who are taking oral warfarin, new anticoagulants such as rivaroxaban and dabigatran due to other diseases; 5. Those who are allergic to ropivacaine and celecoxib; 6. Those who have not completed surgery within 48 hours.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subjective pain level; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative cognitive function; | — |
Countries
China
Contacts
Public ContactWeiwei Zhan
Sinopharm Gezhouba Central Hospital
Outcome results
None listed